Evidence map›Paper›PMID 30127788›Full record

ArticleFrontiers in immunology2018

Conditional Selection of B Cells in Mice With an Inducible B Cell Development.

Elias Hobeika, Marcel Dautzenberg, Ella Levit-Zerdoun, Roberta Pelanda, Michael Reth

Abstract read
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Elias HobeikaCentre for Biological Signaling Studies (BIOSS), Biology III, Faculty of Biology, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.
Marcel DautzenbergCentre for Biological Signaling Studies (BIOSS), Biology III, Faculty of Biology, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.
Ella Levit-ZerdounMax Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
Roberta PelandaDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
Michael RethCentre for Biological Signaling Studies (BIOSS), Biology III, Faculty of Biology, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Developing B cells undergo defined maturation steps in the bone marrow and in the spleen. The timing and the factors that control these differentiation steps are not fully understood. By targeting the B cell-restricted

Indexed as

LymphopoiesisAnimalsAntibodies, Anti-IdiotypicB-Cell Activating FactorB-LymphocytesBone MarrowCD79 AntigensCell LineCell SeparationCell SurvivalGenes, bcl-2MiceMice, Inbred BALB CModels, ImmunologicalPrecursor Cells, B-LymphoidReceptors, Antigen, B-CellAntibodies, Anti-Idiotypicanti-IgMB-Cell Activating FactorCD79 AntigensReceptors, Antigen, B-CellTamoxifenB cell activating factorB cell developmentCre/loxPIg-αimb-1 mouseMerCreMertamoxifentransitional B cells

Identifiers

PMID30127788
PMCPMC6087743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.